Keratinocyte cancer
detection
Extending detection beyond melanoma
Keratinocyte cancers – including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) – are the most common skin cancers. Nevisense supports detection of these cancers using the same EIS and AI technology proven in melanoma diagnostics.
Why Nevisense
-
Supports detection of both BCC and SCC.
-
Provides objective, non-invasive lesion assessment.
-
Helps prioritize lesions for biopsy and treatment.
One platform, broader use
Nevisense allows clinicians to assess both melanoma and non-melanoma lesions using a single system, enhancing its value across dermatology practices.
Non-invasive lesion evaluation
By detecting structural tissue changes, Nevisense helps triage lesions that require biopsy or treatment, reducing diagnostic uncertainty.
Early intervention support
Early identification of BCC and SCC enables timely treatment, improving patient outcomes and reducing healthcare costs.
Benefits for clinical teams
Nevisense helps:
• Dermatologists manage high lesion volumes efficiently
• Primary care providers improve triage decisions
• Cancer care teams coordinate earlier interventions
Get in touch with us
Have questions or want to learn more? Contact SciBase to discover how our solutions can support your work.